Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 11337
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608356(US11691989, Compound 14 | US11691989, Compound 15 ...)
Affinity DataIC50: 2nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608352(US11691989, Compound 10 | (Z)-15-chloro-13,25,61-t...)
Affinity DataIC50: 4nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608376(US11691989, Compound 32 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608393(US11691989, Compound 49 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608391(US11691989, Compound 47 | (Z)-15-chloro-13,21,25,6...)
Affinity DataIC50: 5nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608233(US11691989, Compound 1 | (Z)-15-chloro-13,61-dimet...)
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608382(US11691989, Compound 38 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM333146(US10196404, Example 1 | Compound I | US10196404, E...)
Affinity DataIC50: 7nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608390(US11691989, Compound 46 | (Z)-15-chloro-13,21,25,6...)
Affinity DataIC50: 8nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608347(US11691989, Compound 5 | US11691989, Compound 6 | ...)
Affinity DataIC50: 9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608383(US11691989, Compound 39 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 9nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608363(US11691989, Compound 21 | (Z)-15,96-difluoro-13,21...)
Affinity DataIC50: 10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608361(US11691989, Compound 19 | (Z)-15-chloro-13,96-difl...)
Affinity DataIC50: 10nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608392(US11691989, Compound 48 | (Z)-15-chloro-13,21,23,6...)
Affinity DataIC50: 12nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608384(US11691989, Compound 40 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 13nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608372(US11691989, Compound 28 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608340(US11691989, Compound 2 | Z)-15-chloro-96-fluoro-13...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608370(US11691989, Compound 26 | Z)-15-chloro-13,23,61-tr...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608362(US11691989, Compound 20 | (Z)-15-cyano-96-fluoro-1...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608345(US11691989, Compound 3 | Z)-15-chloro-96-fluoro-13...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608346(US11691989, Compound 4 | (Z)-15-chloro-96-fluoro-1...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608351(US11691989, Compound 9 | (Z)-13,15-dichloro-21,25,...)
Affinity DataIC50: 14nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608359(US11691989, Compound 17 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608353(US11691989, Compound 11 | (Z)-15-chloro-21-(2-meth...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608379(US11691989, Compound 35 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608371(US11691989, Compound 27 | (Z)-15-chloro-21-(2-meth...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608360(US11691989, Compound 18 | (Z)-15-chloro-25-(difluo...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608364(US11691989, Compound 22 | (Z)-96-fluoro-13,15,21,2...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608368(US11691989, Compound 24 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 15nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608375(US11691989, Compound 31 | (Z)-15-chloro-4-(cyclopr...)
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608389(US11691989, Compound 45 | (Z)-15-chloro-25-(difluo...)
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608365(US11691989, Compound 23 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 16nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608395(US11691989, Compound 51 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608374(US11691989, Compound 30 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608347(US11691989, Compound 5 | US11691989, Compound 6 | ...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608385(US11691989, Compound 41 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 17nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608354(US11691989, Compound 12 | (Z)-13-(acetamidomethyl)...)
Affinity DataIC50: 18nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608356(US11691989, Compound 14 | US11691989, Compound 15 ...)
Affinity DataIC50: 19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608355(US11691989, Compound 13 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 19nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608394(US11691989, Compound 50 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 20nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608369(US11691989, Compound 25 | (Z)-15-chloro-13-cyano-9...)
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608350(US11691989, Compound 8 | (Z)-15-chloro-13-ethyl-21...)
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608396(US11691989, Compound 52 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 21nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608386(US11691989, Compound 42 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608387(US11691989, Compound 43 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 22nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608388(US11691989, Compound 44 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 23nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608399(US11691989, Compound 55 | Z)-15-chloro-96-fluoro-1...)
Affinity DataIC50: 24nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608380(US11691989, Compound 36 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608398(US11691989, Compound 54 | (Z)-15-chloro-4-(2-(dime...)
Affinity DataIC50: 27nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [171-323](Human)
Ascentage Pharma (Suzhou)

US Patent
LigandPNGBDBM608381(US11691989, Compound 37 | (Z)-15-chloro-96-fluoro-...)
Affinity DataIC50: 29nMAssay Description:The relative binding potency of representative Compounds of the Disclosure was determined by a fluorescence polarization (FP) assay. The method used ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/6/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: